This panel discussion delves into the critical role of Homologous Recombination Deficiency (HRD) in guiding treatment strategies for ovarian cancer. Experts will discuss how HRD testing, including BRCA1/2 mutation analysis and Genomic Scar Score (GSS) determination, identifies patients who may benefit from PARP inhibitor therapy. The panel will explore the latest clinical evidence, challenges in HRD testing implementation, and the evolving landscape of personalized medicine in ovarian cancer. Discussions will focus on optimizing patient selection, interpreting complex HRD results, and the impact of HRD-directed therapies on patient outcomes. This event aims to advance understanding and improve patient care by highlighting the therapeutic potential of HRD assessment in ovarian cancer.